Table 1.
Patient characteristics of stage 2 and 3 rectal cancer who received traditional therapy or induction chemotherapy (IC)
| Patient characteristics | Traditional (N = 33 012) | IC (N = 3241) | P value |
|---|---|---|---|
| Mean age (SD), n (%) | 59.7 (12.2) | 58.6 (12.3) | <0.001 |
| <50 years old | 7676 (23.3) | 836 (25.8) | |
| 50‐60 years old | 9694 (29.4) | 978 (30.2) | |
| 60‐70 years old | 8949 (27.1) | 863 (26.6) | |
| 70 + years old | 6693 (20.3) | 564 (17.4) | |
| Female | 12 386 (37.5) | 1216 (37.5) | 1.0 |
| Race/ethnicity, n (%) | <0.001 | ||
| White | 28 754 (87.1) | 2717 (83.8) | |
| Black | 2487 (7.5) | 324 (10.0) | |
| Asian | 1323 (4.0) | 143 (4.4) | |
| Other | 448 (1.4) | 57 (1.8) | |
| Hispanic | 1777 (5.6) | 269 (8.6) | |
| Insurance, n (%) | <0.001 | ||
| Private insurance | 17 113 (51.8) | 1713 (52.9) | |
| Medicare | 11 248 (34.1) | 991 (30.6) | |
| Medicaid | 2248 (6.8) | 263 (8.1) | |
| Other government insurance | 488 (1.5) | 43 (1.3) | |
| Not insured | 1509 (4.6) | 189 (5.8) | |
| Income quartiles, n (%) a | <0.001 | ||
| <38K | 5593(17.0) | 595 (18.5) | |
| 38K‐48K | 8244 (25.1) | 680 (21.2) | |
| 48K‐63K | 9017 (27.5) | 819 (25.5) | |
| >63K | 9963 (30.4) | 1120 (34.9) | |
| Education, n (%) a , b | <0.001 | ||
| ≥29% (lowest edu) | 5098 (15.9) | 602 (19.3) | |
| 20%‐28.9% | 7.738 (24.2) | 733 (23.4) | |
| 14%‐19.9% | 7979 (25.0) | 714 (22.8) | |
| <14% (highest edu) | 11 165 (34.7) | 1079 (34.5) | |
| Urban/rural patient location, n (%) | <0.001 | ||
| Metropolitan | 25 173 (78.1) | 2595 (83.3) | |
| Urban/Suburban | 6166 (19.1) | 443 (14.2) | |
| Rural | 911 (2.8) | 76 (2.4) | |
| Average distance travelled to hospital (SD), miles | 31.5 (104.7) | 30.3 (102.4) | 0.56 |
| Rectal cancer clinical stage | <0.001 | ||
| Stage 2 | 15 305 (46.4%) | 1311 (40.5%) | <0.0001 |
| T3 | 13 342 | 1076 | |
| T4a | 559 | 64 | |
| T4b | 453 | 78 | |
| Stage 3 | 17 707 (53.6%) | 1930 (59.6%) | <0.001 |
| T1/2N1 | 2791 | 146 | |
| T1N2a | 19 | 4 | |
| T1/2N2b | 20 | 5 | |
| T2/3N2a | 1966 | 226 | |
| T3/4aN1 | 10 499 | 1299 | |
| T4aN2a | 178 | 26 | |
| T3/4aN2b | 277 | 43 | |
| T4bN1/2 | 603 | 105 | |
| Charlson/Deyo score, n (%) | 0.35 | ||
| 0 | 26 314 (79.7) | 2588 (79.9) | |
| 1 | 5383 (16.3) | 516 (15.9) | |
| 2 | 1001 (3.0) | 96 (3.0) | |
| 3 | 314 (1.0) | 41 (1.3) | |
| Stage 4 on pathology | 434 (2.6) | 52 (3.1) | 0.18 |
| Receipt of postoperative chemotherapy | 11 513 (34.9) | 941 (29.0) | <0.001 |
| Path stage 2/3 | 6415 | 512 | |
| Path stage 4 | 167 | 18 | |
| Complete regression on pathology, n (%) | 3698 (30.4) | 370 (32.2) | 0.2 |
a
Assigned by zipcode of patient's residence.
b
Proportion of population without high school degree.